

Sareum Holdings plc

("Sareum" or the "Company")

US patent allowance for its lead programme SDC-1801

- Notice of Allowance from US Patent and Trademark Office received

Cambridge, UK, 2 September 2024 -Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent on SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases.

The US patent, application number US2021387981, will offer substantial protection on the chemical structure of SDC-1801 and an analogue, their use in treating inflammatory diseases and in certain methods of their chemical synthesis.

Sareum has now secured patent coverage in the major territories, following patent approvals by the European Patent Office, China National Intellectual Property Administration and Japan Patent Office for the same protections. The Company expects the US patent to be granted by the end of 2024, subject to the fulfilment of certain formalities with the USPTO.

Dr John Reader, Sareum's Chief Scientific Officer, commented *"We are pleased to extend the patent protection for SDC-1801 on the back of the encouraging data from our Phase 1a trial, indicating our inhibitor could confer significant advantages over other TYK2/JAK1 kinase inhibitors. We remain motivated in progressing SDC-1801 through clinical development to develop new therapeutics for autoimmune diseases and cancers."*

- Ends -

For further information, please contact:

Sareum Holdings plc

Stephen Parker, Executive Chairman

01223 497700
ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Hybridan LLP (Corporate Broker)

Claire Noyce

020 3764 2341

ICR Consilium (Financial PR)

Jessica Hodgson / Davide Salvi / Kumail Waljee

0203 709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEANNFEEXLEFA